Helixmith Co., Ltd.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Helixmith Co., Ltd.
After probing pharmacokinetic data flaws in the first US Phase III study for its gene therapy Engensis, Korea's Helixmith concludes that these stemmed from clinical operation issues. As a result, it admits a failure to meet the primary endpoint but is still moving forward with new trials given signals of efficacy and safety in an extended study.
The South Korean pharma/biotech industry suffered a series of negative blows in 2019 but there were still notable achievements including major drug approvals and large-scale licensing deals.
After a lackluster year so far for South Korean biotech IPOs amid disappointing clinical trial news, investor interest is beginning to pick up, with several companies that have been under the spotlight slated to debut on the market in the coming months.
South Korea will undergo many changes as it gears up for a new law on cutting edge regenerative medicine and biologics, which will be implemented next year. Until then, further discussions will be needed to set details of the rules that can step up the industry’s competitiveness and bring the country more in line with global standards.
- Drug Delivery
- Gene Therapy, Cell Therapy
Drug Discovery Tools
- Natural Products
- Molecular Diversity
- Other Names / Subsidiaries
- ViroMed Co., Ltd.
- VM BioPharma
- Genebiotech Co., Ltd